PCOS, Thyroid, and Trying to Conceive: The TSH Target and Dose Timing

Why does thyroid function matter more once you’re trying to conceive with PCOS?

Thyroid autoimmunity shows up roughly three times more often in women with PCOS than in women without it — 26.9% versus 8.3% in a study of 175 women with PCOS and 168 matched controls (Janssen et al., 2004) — which means the thyroid questions in this article apply to a meaningfully larger share of this readership than of the general population trying to conceive. That overlap is also why thyroid function is checked routinely as part of a standard PCOS diagnostic work-up, alongside the androgen and ovulation testing that explains most PCOS-related infertility (Teede et al., 2023) and sits inside the wider PCOS fertility work-up rather than as a stand-alone concern. This article is not a general PCOS-and-thyroid comparison — that overlap in symptoms and diagnostic testing is its own subject — it covers what changes specifically once you are actively trying to conceive: the target itself shifts, the timeline gets tighter, and a normal result today does not mean the same thing it did last year.

Note: in May 2026, PCOS was renamed polyendocrine metabolic ovarian syndrome, or PMOS, by a global consensus of more than 50 organisations. Same condition, same mechanism — only the label changed. This article uses PCOS, since that is still the term most readers search.

What TSH target applies once you’re trying to conceive, and how is it different from a standard range?

The American Thyroid Association’s 2017 guideline moved away from a single fixed TSH cutoff toward population-specific, trimester-specific reference ranges wherever a lab has them, precisely because a universal number does not reflect real geographic and ethnic variation (Alexander et al., 2017). When a local range is not available, the guideline’s own fallback calculation is to reduce the standard non-pregnant upper limit by approximately 0.5 mU/L, which works out to a TSH upper reference limit of about 4.0 mU/L for a typical patient in the late first trimester (weeks 7–12), gradually returning toward the non-pregnant range in the second and third trimesters. That is looser than the flat 2.5 mU/L figure that circulated widely after the prior 2011 guideline — a detail worth knowing before you compare an old printout of “the number” against what your current lab actually reports.

Separately, for women already being treated for hypothyroidism who are actively planning pregnancy, the same guideline recommends optimizing thyroid levels before conception, with a maternal TSH below 2.5 mU/L as a reasonable preconception goal (Alexander et al., 2017). For women with subclinical hypothyroidism specifically undergoing IVF or ICSI, the same guideline recommends levothyroxine treatment targeted to that same TSH threshold, below 2.5 mU/L, because the evidence supporting treatment is stronger in the ART setting than for people trying to conceive naturally.

These are the guideline’s own targets, not a number to apply to your own result on your own. Where you sit relative to any of these is a conversation to have with whoever manages your thyroid care, not a self-diagnosis exercise — the same guideline stresses that method-specific and trimester-specific ranges vary by lab and by assay, so the same raw number can mean something different depending on where it was drawn.

Why might your levothyroxine dose need to rise before you even miss a period?

Between 50% and 85% of women already treated with levothyroxine need an increased dose during pregnancy, and the increased demand can begin as early as 4 to 6 weeks of gestation — before many people have taken a pregnancy test, let alone seen a clinician for the first time (Alexander et al., 2017). The foundational study behind this finding followed 20 pregnancies in 19 women with hypothyroidism and found that 85% of them required a dose increase of roughly 50%, occurring almost entirely in the first trimester, with the first documented increase as early as week 5 in some patients (Alexander et al., 2004). This is arguably the single most actionable fact in this article: the demand for thyroid hormone rises before your body gives you any other signal that you’re pregnant.

Is a positive thyroid antibody test with otherwise “normal” levels something to treat?

This is the part of the picture where the evidence is genuinely unsettled, and it deserves an honest answer rather than a confident one. Thyroid peroxidase (TPO) antibodies mark autoimmune thyroid activity even when TSH and free T4 both sit within the normal range — a state usually called euthyroid TPO-positivity — and a 2011 meta-analysis of more than 12,000 women found the presence of thyroid antibodies associated with nearly 4 times the odds of miscarriage in cohort studies and roughly double the odds of preterm birth (Thangaratinam et al., 2011). Two small earlier trials pooled in that same analysis suggested levothyroxine treatment could roughly halve the miscarriage rate in TPO-positive women, which is the finding that shaped clinical practice for years afterward.

The largest and most rigorous trial to test that idea directly did not confirm it. The TABLET trial randomized 952 euthyroid, TPO-antibody-positive women with a history of miscarriage or infertility to levothyroxine or placebo before conception, continuing through pregnancy, and found no difference in live birth rate between the two groups (Dhillon-Smith et al., 2019). That is a much larger and more definitive trial than the ones that came before it, and it points the other way. The honest summary is that the association between TPO antibodies and pregnancy loss is real and well-documented, but the largest trial of the obvious fix — levothyroxine — did not show it improves the outcome that matters most. The 2017 ATA guideline reflects exactly this uncertainty: it makes no recommendation for or against levothyroxine in euthyroid, TPO-positive women attempting natural conception, citing insufficient evidence either way (Alexander et al., 2017).

What is well established, regardless of the treatment question, is that TPO-positive women are more likely to develop an elevated TSH as pregnancy progresses even when they started out euthyroid — in one frequently cited study, TSH rose from an average of 1.7 mU/L at 12 weeks to 3.5 mU/L at term, with about 1 in 5 women crossing into an abnormal range by delivery (Alexander et al., 2017). That is the practical reason a positive TPO result is still worth knowing even if no treatment is started immediately: it identifies who needs closer monitoring through pregnancy, separate from whether levothyroxine gets started before a TSH actually rises out of range.

Could your iron supplement be blocking your thyroid medication?

Levothyroxine absorption drops measurably when it is taken alongside iron or calcium, which is specifically relevant here because iron supplementation is common in this readership: in a 12-week study of patients on stable levothyroxine, adding daily ferrous sulfate raised TSH in 11 of 14 patients, with 9 developing symptoms of hypothyroidism, and lab testing confirmed that iron and thyroid hormone form an insoluble complex in the gut when taken together (Campbell et al., 1992). Calcium behaves similarly: co-administering calcium carbonate with levothyroxine measurably reduced total thyroxine absorption over the following hours in a controlled pharmacokinetic study (Zamfirescu & Carlson, 2011).

The standard fix is separation, not avoidance: taking levothyroxine at least 4 hours apart from any iron- or calcium-containing product — including a prenatal vitamin, since most prenatal formulas contain iron and many contain calcium. This matters twice over for someone with PCOS who is also managing iron deficiency, which is common enough in this readership to be easy to miss, and for anyone working out when to start a prenatal vitamin alongside an existing levothyroxine prescription. Neither product needs to be dropped; they simply cannot be taken at the same time of day without one interfering with the other.

How often should thyroid levels be rechecked once you’re trying or pregnant?

Once pregnancy is confirmed or even strongly suspected, the ATA guideline recommends dose adjustment as soon as possible, followed by TSH testing roughly every 4 weeks until the midpoint of pregnancy, and at least once more near 30 weeks (Alexander et al., 2017). Women who are TPO-positive but not yet on levothyroxine are generally monitored on a similar roughly-monthly schedule through the first half of pregnancy, precisely because of the TSH-creep pattern described above. None of this testing needs to wait for a scheduled prenatal visit if your usual thyroid prescriber can run it sooner — the entire rationale for early dose adjustment depends on not waiting.

Who this does not apply to

If your thyroid panel is normal and your TPO antibodies are negative, none of the dose-timing urgency above applies to you — this article is specifically for people already on levothyroxine or already known to be TPO-positive. A single normal TSH result also does not mean you can skip retesting once you conceive: normal now and normal in the second trimester are two different measurements, not one confirmation that covers both. And nothing here is a substitute for asking a fertility specialist to coordinate thyroid monitoring with the rest of your fertility treatment if you are also doing ovulation induction or IVF — the targets in Table 1 above assume someone is actually tracking them on a schedule, not that they apply themselves.

Frequently asked questions

Your next step

If you’re already on levothyroxine and actively trying to conceive, ask your prescriber two things now, before a positive test: what TSH number they want you at preconception, and exactly what to do with your dose the day you get a positive result. If you’ve never had a TPO antibody test and have PCOS, ask for one alongside your other preconception labs — not because a positive result changes anything immediately, but because it tells you and your prescriber whether closer monitoring is worth setting up in advance.